August 31, 2005

Anne E. White named Chief Operating Officer and VP of Clinical Operations of Tigris Pharmaceuticals

NEW YORK, August 31, 2005 - Tigris Pharmaceuticals, Inc., a development stage biopharmaceutical company, is pleased to announce the appointment of Anne E. White as its Chief Operating Officer and Vice President of Clinical Operations. Ms. White brings 15 years of drug development experience in oncology, infectious disease, and neuroscience.

"Ms. White's depth of experience in clinical operations makes her an excellent addition to Tigris, and I look forward to working with her toward the successful development of our drug candidates," said Dr. Edmundo Muniz, Tigris' President and Chief Executive Officer.

Prior to joining Tigris, Ms. White worked at Eli Lilly and Company since 1990, where she most recently served as the Chief Operating Officer for the Global Oncology Platform. In her most recent position at Lilly Oncology, Ms. White was responsible for the clinical development of three oncology molecules, both pre- and post-registration. During Ms. White's tenure, Lilly Oncology submitted 9 major applications in the US, EU and Japan and initiated over 100 clinical studies globally. Ms. White was also named Lilly's Women's Network Award Winner in 2005.

Prior to her oncology leadership role, Ms. White acted as Chief Operating Officer for the Infectious Diseases Product Team at Eli Lilly. In this position, Ms. White was responsible for the clinical development program, in partnership with a global Contract Research Organization, and the subsequent out-licensing of oritavancin, a compound for the treatment of skin structure infections and bacteremia. Ms. White's earlier roles in Lilly were in the neuroscience platform, where she was responsible for clinical operations for several key Lilly molecules, including Prozac. Also while at Lilly, Ms. White was responsible for several major efficiency improvement efforts, resulting in significant positive impact to Lilly's clinical development teams.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that acquires the rights to commercially develop therapeutic technologies to address unmet medical needs. Tigris is currently developing a topical treatment for pre-cancerous and cancerous anogenital lesions associated with the human papillomavirus (HPV), which is expected to enter Phase II human clinical trials in late 2005. The company's mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contact:

Edmundo Muniz
President and Chief Executive Officer
Tigris Pharmaceuticals, Inc.
info@tigrispharma.com

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.